Viking Therapeutics, Inc. - Common Stock (VKTX)
CUSIP: 92686J106
Q4 2015 13F Holders as of 31 Dec 2015
- Type / Class
- Equity / Common Stock
- Shares outstanding
- 113,177,462
- Total 13F shares
- 41,278
- Share change
- -1,897
- Total reported value
- $140,000
- Price per share
- $3.36
- Number of holders
- 5
- Value change
- -$14,614
- Number of buys
- 2
- Number of sells
- 3
Quarterly Holders Quick Answers
What is CUSIP 92686J106?
CUSIP 92686J106 identifies VKTX - Viking Therapeutics, Inc. - Common Stock in SEC institutional holdings data.
Need full ownership history?
Open the full security ownership history page.
Related Filing Research
- Latest 13F filings for newly reported positions.
- Latest Schedule 13D/13G reports for ownership changes outside 13F cadence.
- Latest 10-Q/10-K reports for financial context tied to this issuer.
- Recent insider transactions for executive and insider activity.
- SEC investors directory and top value investors for manager drilldown.
- Back to full security ownership history.
Explore More Reporting Periods
Jump to adjacent filing periods for faster comparison and easier crawl discovery.
Recent filing periods for CUSIP 92686J106:
Top shareholders of VKTX - Viking Therapeutics, Inc. - Common Stock (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| GOLDMAN SACHS GROUP INC |
13F
|
Company |
0.02%
|
18,262
|
$107,000 | — | 30 Sep 2015 | |
| VANGUARD GROUP INC |
13F
|
Company |
0.02%
|
18,275
|
$106,000 | — | 30 Sep 2015 | |
| Creative Planning |
13F
|
Company |
0%
|
3,000
|
$18,000 | — | 30 Sep 2015 | |
| Tower Research Capital LLC (TRC) |
13F
|
Company |
0%
|
1,903
|
$11,000 | — | 30 Sep 2015 | |
| UBS Group AG |
13F
|
Company |
0%
|
1,408
|
$8,000 | — | 30 Sep 2015 | |
| BlackRock Investment Management, LLC |
13F
|
Company |
0%
|
327
|
$2,000 | — | 30 Sep 2015 |
Institutional Holders of Viking Therapeutics, Inc. - Common Stock (VKTX) as of Q4 2015
As of 31 Dec 2015,
Viking Therapeutics, Inc. - Common Stock (VKTX) was held by
5 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
41,278 shares.
The largest 5 holders included
VANGUARD GROUP INC, GOLDMAN SACHS GROUP INC, WELLS FARGO & COMPANY/MN, Creative Planning, and BlackRock Investment Management, LLC.
This page lists
5
institutional shareholders reporting positions in this security
for the Q4 2015 filing period.
| Investor | Option | Weight % | Change % | Value $ | * Price | Shares | Share Change | Activity | Report Period |
|---|
Compare Q4 2015 vs Q3 2015 Across Filers
Q3 2015 holders
6
Q4 2015 holders
5
Holder diff
-1
| Investor | Q3 2015 Shares | Q4 2015 Shares | Share Diff | Share Chg % | Q3 2015 Value $ | Q4 2015 Value $ | Value Diff $ | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.
An asterisk sign (*) next to the price indicates that the price is likely invalid.